Additionally, it is now evident that oncogene mutations affect the progression of AML and some of these mutated genes are FLT3, NPM1 and CEBPA (Grove & Vassiliou, 2014; Meyer & Levine, 2014). This evidence concerns the gene NPM1 and acute myeloid leukemia.